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ABSTRACT
Introduction: The completeness of the pathological examination of resected colon cancer
specimens is important for further clinical management. We reviewed the pathological
reports of 356 patients regarding the five factors (pT-stage, tumor differentiation grade, lym-
phovascular invasion, tumor perforation and lymph node metastasis status) that are used to
identify high-risk stage II colon cancers, as well as their impact on overall survival (OS).
Methods: All patients with stage II colon cancer who were included in the first five years of
the MATCH study (1 July 2007 to 1 July 2012) were selected (n¼ 356). The hazard ratios of
relevant risk factors were calculated using Cox Proportional Hazards analyses.
Results: In as many as 69.1% of the pathology reports, the desired information on one or
more risk factors was considered incomplete. In multivariable analysis, age (HR: 1.07, 95%CI
1.04–1.10, p< .001), moderately- (HR: 0.35, 95%CI 0.18–0.70, p¼ .003) and well (HR 0.11,
95%CI 0.01–0.89, p¼ .038) differentiated tumors were significantly associated with OS.
Conclusions: Pathology reports should better describe the five high-risk factors, in order to
enable proper patient selection for further treatment. Chemotherapy may be offered to stage
II patients only in select instances, yet a definitive indication is still unavailable.
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Colorectal cancer is currently the second most
common malignancy in the Western world [1].
Overall, 50–60% of the patients diagnosed with
colorectal cancer will develop metastases [2–6].
The risk of developing metastases as well as sur-
vival can be estimated more accurately for the
individual patient by taking into consideration the
American Joint Committee on Cancer (AJCC) TNM
classification [7]. The pathological TNM classifica-
tion is the most important factor to determine the
therapeutic approach [8].
For colon cancer, curatively resectable tumors
are divided into AJCC stage I to III, with stage III
necessitating adjuvant chemotherapy in addition
to watchful waiting strategies. Patients with stage
II colon carcinoma are thought not to require adju-
vant chemotherapy in most cases [9,10]. However,
the American Society of Clinical Oncology (ASCO)
guidelines propose a subdivision of stage II
patients into low and high-risk. This subdivision is
based on five high-risk factors: T-stage, tumor dif-
ferentiation grade, lymphovascular invasion (LVI),
tumor perforation and, most importantly, lymph
node metastasis status [9]. In high-risk patients,
adjuvant chemotherapy can be considered,
while adjuvant chemotherapy has no place in
the treatment of low-risk stage II colon cancer
patients [9,11].
Because of their importance and clinical implica-
tions, the pathology reports of colon cancer speci-
mens should include a statement regarding the
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five aforementioned factors. In addition to the five
high-risk factors, molecular subtypes of cancer
have been previously reported to have an effect on
overall survival (OS) as well [12]. In particular,
patients with microsatellite instability (MSI) are
reported to have higher OS [12]. To optimize the
accuracy of pathology reports on colorectal cancer
specimens, the Dutch federation for pathology
in 2008 drew up the guideline ‘Protocol
Colonrectum’, summarizing which factors should
be included in a pathology report and how [13].
The reporting of the five high-risk factors was facul-
tative until early 2012, when the reporting of the
factor LVI became mandatory [13].
In this study, a cohort of 356 patients was
reviewed to determine the accuracy and complete-
ness regarding the five factors used to identify
high-risk stage II colon cancers. We performed a
detailed analysis of nodal status, which is consid-
ered the most important risk factor [6].
Methods
Patient selection
Patients were selected from the MATCH study
(MEC-2007-088), an ongoing prospective registra-
tion cohort including all patients who undergo
curative surgery for primary colorectal cancer in
seven hospitals in the Rotterdam region. All
patients with stage II colon cancer who were
included in the first five years of the MATCH study
(1 July 2007 to 1 July 2012) were selected. All
patients gave written informed consent.
Scoring pathology report
Pathology reports were examined for the exist-
ence of a statement on the five factors used to
identify high-risk stage II patients: pathological
T-stage (pT-stage), N-stage, tumor differentiation
grade, LVI and tumor perforation. For the T-stage,
tumor differentiation grade and LVI the presence
or absence of a statement regarding these tumor
characteristics was scored. For the N-stage,
patients with more than 10 harvested lymph
nodes were considered to have an N0 stage,
while patients with less than 10 harvested lymph
nodes were considered to have an Nx stage. In
Nx patients, the presence or absence of a specific
comment regarding the low total lymph node
yield was scored. Tumor perforation was planned
only to be scored present or absent in case of a
clinical suspicion for perforation. As no patients
had a clinical suspicion of tumor perforation, this
factor was not scored. Data on MSI were not rou-
tinely scored. However, since MSI is highly corre-
lated with right-sidedness of the tumor, we used
this as a dummy variable [12]. Pathological risk
factors associated with lower survival in stage II
patients were individually examined in our
patient cohort for both differences in clinicopa-
thologic characteristics of patients, as well as sur-
vival analyses.
Statistical analysis
Summary statistics were provided as percentages
of categorical variables and medians with
interquartile ranges of continuous variables.
Comparison of categorical variables was performed
using the Pearson chi-square test, while continuous
variables were compared using the Kruskal–Wallis
test. OS estimates and figures were created using
the Kaplan–Meier method. Patients who expired
within three months postoperatively were
excluded from the survival analysis. Differences in
survival amongst the different risk factors were
assessed using the Log-Rank test. The hazard ratios
of relevant risk factors, along with their 95%CIs,
were calculated using Cox Proportional Hazards
analyses. Conditional backwards selection with all
relevant risk factors was conducted, based on the
probability of the likelihood-ratio statistic based on
conditional parameter estimates. All analyses were
carried out with SPSS 22 (IBM, Armonk, NY). All




As shown in Figure 1, in 69.1% of the pathology
reports the information on one or more risk factors
was considered incomplete (61.2% 1 factor, 7.9% 2
factors). T-stage and N-stage were reported in all
cases. However, in the 44 Nx patients, the path-
ology report did not comment on this total yield
as being a risk factor. In 62.8% of all cases, no
statement regarding presence or absence of LVI
was recorded; tumor differentiation grade was not
reported in 2.3%. As mentioned in the introduc-
tion, the reporting of LVI became mandatory in
2012. LVI, regardless whether present or absent,
was reported significantly more after mandating
the reporting of this risk factor (33.5% vs. 87.5%;
p< .001).
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Clinicopathological characteristics
Total baseline and other characteristics compared
by N-stage are shown in Table 1. Just over half
(n¼ 193, 54.2%) of the patients were male. The
median age was 71 years (IQR 64–79 years). A diag-
nostic colonoscopy was performed in 327 (96.2%)
of the patients and 320 (89.9%) patients under-
went staging CT imaging. A small subgroup of
patients received additional abdominal ultrasound
(n¼ 104, 29.2%), MRI (n¼ 8, 2.2%), or PET-scan
(n¼ 1, 0.3%). More than two-thirds of patients had
an American Society of Anesthesiologists (ASA)
classification score of 2 (n¼ 195, 70.1%). At the
time of surgery, half of the patients underwent lap-
aroscopic surgery (n¼ 174, 49.4%) and most
patients underwent a right (n¼ 172, 49.0%) or left
sided hemicolectomy (n¼ 169, 48.1%). The major-
ity of patients had a T3 (n¼ 324, 91.0%), whereas a
small minority had a T4 tumor (n¼ 32, 9.0%). Of
our 356 patients, 312 (87.6%) patients did not have
lymph node metastases and had more than 10
nodes, while 44 (12.4%) did not have the required
minimum of 10 nodes. Over three quarters of the
patients had a moderately differentiated tumor
(n¼ 298, 83.9%). A small subgroup of patients
(n¼ 21, 5.9%) received adjuvant therapy. In all, 13
patients (4.1%) expired within 90 days and were
therefore excluded in survival analyses.
Differences between the patients with and with-
out high-risk factors were more closely evaluated
(Table 1, Supplementary Table 1–3). Between the
Nx and N0 group, a significant difference was
observed in median age, with the Nx group being
significantly older (71 vs 75 years, p¼ .029). T4
patients as opposed to T3 patients received adju-
vant chemotherapy (37.5% vs. 2.8%, p< .001) more
often, and had an unknown (not reported) differ-
entiation grade of their tumor relatively more fre-
quently (9.4% vs. 1.5%, p¼ .021). No clinical
differences were observed between patients with
demonstrated LVI, patients without LVI, and
patients in whom this factor was not recorded in
the pathology report. Finally, there was a trend
towards administering chemotherapy in patients
with worse tumor differentiation (p¼ .086).
Overall survival per high-risk factor
Median follow-up in our cohort was 72.4 months
(IQR 62.8–80.8). The 1-, 3- and 5-year survival was
98.0%, 89.1 and 80.4%, respectively. When
Figure 1. Overall reporting of high-risk factors (N-stage, T-stage, lymphovascular invasion, and tumor differentiation) in the
pathology report. N-stage pathology report scoring. T-stage pathology report scoring. Lymphovascular invasion pathology
report scoring. Tumor differentiation pathology report scoring.
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examining high-risk factors more closely in our
cohort of stage II patients we found that these risk
factors did not seem to have a significant impact
on survival (Figure 2). In our study, we did not find
a significant association between the failure to
report any of the five factors and overall survival.
No difference was found between left-sided colo-
rectal cancer, right-sided colorectal cancer and
colorectal cancer on both sides. As depicted in the
Kaplan–Meier graphs, no trend towards a differ-
ence was visible for any of the risk factors either
(Table 2). Age (HR: 1.06, 95%CI 1.03–1.08, p< .001)
and ASA Class 3 (HR: 3.52, 95%CI 1.19–10.42,
p¼ .023) were significantly associated with OS in
univariable analysis. In multivariable analysis age
(HR: 1.07, 95%CI 1.04–1.10, p< .001), moderately
(HR: 0.35, 95%CI 0.18–0.70, p¼ .003) and well (HR
0.11, 95%CI 0.01–0.89, p¼ .038) differentiated
tumors were significantly associated with OS, after
conditional backwards selection of associated
variables.
Discussion
Colorectal cancer is currently one of the most com-
mon malignancies in the Western world [1]. For
colon cancer, tumors are divided into stage I to IV
with a subdivision for stage II patients into low-
and high-risk patients, based on the factors
pT-stage, tumor differentiation grade, LVI, tumor
perforation and, most importantly, lymph node
metastasis status. In this study, a set of 356 path-
ology reports was reviewed to determine the
accuracy and completeness regarding the five fac-
tors used to identify high-risk stage II colon cancers
and the impact on clinical management.
In 2007, Quirke et al. suggested three main rea-
sons for the incompleteness of pathology: the
ignorance of the importance of certain features for
clinical management, the large number of possible
prognostic features that could be reported, and
the desire to hold on to free text reports [14].
While the first may be overcome by education and
routine audit with feedback, the second and third
reason requires a standardized minimum set of
items that should be reported. Interestingly, in
1998 the Royal College of Pathologists already sug-
gested such a set which included all five factors
examined in the current study [15]. The use of pro-
forma reporting for pathology reports on colorectal
cancer specimens has been described to increase
the completeness of the reports up to 96% [16,17].
Synoptic reporting, in which a prespecified set of
items have to be scored before the report can be
finalized, has also been described to add to the
completeness of pathology reports [18]. The
Table 1. Clinicopathological characteristics, stratified by nodal status.
Characteristic N0 (n¼ 312) Nx (n¼ 44) p value Total (n¼ 356)
Gender
Female 139 (44.6) 24 (54.5) 163 (45.8)
Male 173 (55.4) 20 (45.5) .213 193 (54.2)
Age, years (IQR) 71 (63–78) 75 (66–82) .029 71 (64-79)
Diabetes 51 (16.9) 2 (4.7) .037 53 (15.4)
Colonoscopy 285 (96.3) 42 (95.5) .789 327 (96.2)
Abdominal ultrasound 94 (30.1) 10 (22.7) .312 104 (29.2)
CT-abdomen 279 (89.4) 41 (93.2) .439 320 (89.9)
MRI abdomen 7 (2.2) 1 (2.3) .990 8 (2.2)
PET-scan 1 (0.3) 0 (0.0) .707 1 (0.3)
ASA class
1 31 (12.9) 1 (2.7) 32 (11.5)
2 167 (69.3) 28 (75.7) 195 (70.1)
3 43 (17.8) 8 (21.6) 51 (18.3)
4 0 (0.0) 0 (0.0) .191 0 (0.0)
Type of operation
Open resection 153 (49.5) 25 (58.1) 178 (50.6)
Laparoscopic resection 156 (50.5) 18 (41.9) .289 174 (49.4)
Type of resection
Left-sided resection 144 (46.8) 25 (58.1) 169 (48.1)
Right-sided resection 154 (50.0) 18 (41.9) 172 (49.0)
(Sub)total colectomy 10 (3.2) 0 (0.0) .232 10 (2.8)
AJCC T-stage
T3 283 (90.7) 41 (93.2) 324 (91.0)
T4 29 (9.3) 3 (6.8) .591 32 (9.0)
Tumor differentation
Poor 32 (10.3) 4 (9.1) 36 (10.1)
Moderate 260 (83.6) 38 (86.4) 298 (83.9)
Well 12 (3.9) 1 (2.3) 13 (3.7)
Unknown 7 (2.3) 1 (2.3) .949 8 (2.3)
Lymphovascular invasion
No 91 (29.3) 12 (27.3) 103 (29.0)
Yes 23 (7.4) 6 (13.6) 29 (8.2)
Unknown 197 (63.3) 26 (59.1) .368 223 (62.8)
Adjuvant therapy 18 (5.8) 3 (6.8) .782 21 (5.9)
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increase of LVI reporting in our data after synoptic
reporting became mandatory substantiates these
earlier observations.
In 2000, the college of American Pathologists
published a statement summarizing and categoriz-
ing the pathologic prognostic factors and predict-
ive factors in colorectal cancer [19]. The pT
category and pN category of the pTNM staging
system as well as LVI were categorized in Category
I, which included factors definitively proven to be
of prognostic import based on evidence from mul-
tiple statistically and methodologically well exe-
cuted published trials. Tumor grade fell into
Category IIA, which included factors extensively
studied clinically and/or biologically and repeatedly
shown to have prognostic and/or predictive value,
but has to be validated in statistically robust stud-
ies. The importance to mention these tumor char-
acteristics was illustrated by Maughan et al., who
reported an association between the failure to
report either vascular invasion or peritoneal
involvement and overall survival in a large retro-
spective study of close to 6000 patients [20].
In our cohort, reporting of most high-risk factors
in stage II patients was absent in the majority of
the pathology reports between 2007 and 2012.
However, a difference in OS between patients in
whom factors indicating worse prognosis were not
reported and those in whom they were absent was
not found. Poorly differentiated tumors performed
worse than moderately and well differentiated
tumors when corrected for age at the time of sur-
gery. Age itself was an independent risk factor as
well. The reasons for the lack of predictive value of
the other four recognized high-risk factors in our
cohort is likely multifactorial. Firstly, this was a pro-
spectively included cohort in which all variables
were scored before the individual disease course
of patients was known, eliminating potential bias
in the scoring of variables. All patients were demo-
graphically similar, as they were treated in the
same region in the Netherlands. This also limited
differences in the quality of health care potentially
correlating with the quality of diagnosis.
The use of adjuvant chemotherapy in stage II
colon cancer patients remains open for discussion.
Current literature does not support the use of adju-
vant chemotherapy for all stage II colon cancer
patients since it does not improve disease-free or
overall survival as illustrated in the MOSAIC trial
[21]. However, the indirect evidence of the benefi-
cial role of adjuvant chemotherapy in stage III
colon cancer patients and the identification of
high-risk stage II colon cancer patients using the
currently available risk factors justifies the consid-
eration of the adjuvant chemotherapy as stated by
Table 2. Survival analysis of stage II colon cancer patients.
Univariable analysis Multivariable analysis
Characteristic HR 95%CI p value HR 95%CI p value
Age, years (IQR) 1.06 1.03–1.08 <.001 1.07 1.04–1.10 <.001
AJCC T-stage
T3 Ref – –
T4 0.84 0.36–1.93 .677
N-stage
N0 Ref – –
Nx 1.29 0.70–2.39 .414
Tumor differentiation
Poor Ref – – Ref – –
Moderate 0.57 0.29–1.11 .097 0.35 0.18–0.70 .003
Well 0.58 0.16–2.11 .409 0.11 0.01–0.89 .038
Lymphovascular invasion
No Ref – –
Yes 1.31 0.58–2.97 .522
Unknown 1.14 0.68–1.93 .617
Diabetes
No Ref – –
Yes 1.25 0.71–2.20 .446
Colonoscopy
No Ref – –
Yes 1.33 0.32–5.42 .694
ASA class
1 Ref – –
2 1.60 0.57–4.46 .371
3 3.52 1.19–10.42 .023
Type of operation
Open resection Ref – –
Laparoscopic resection 1.13 0.72–1.77 .605
Type of resection
Left-sided resection Ref – –
Right-sided resection 1.03 0.65–1.61 .913
(Sub)total colectomy 0.44 0.06–3.23 .422
Adjuvant therapy 0.42 0.10–1.71 .224
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the American Society of Clinical Oncology [9]. In
our study, the use of adjuvant chemotherapy was
not a significant predictor of better overall survival
(HR: 0.42, 95%CI: 0.10–1.71, p¼ .224).
Although it is, to our knowledge, the first study
into the completeness of prognostic factor report-
ing in type II colon cancer patients, this study has
a number of limitations. First of all, our number of
patients is comparatively low. Because our study is
based on primary data of patients with stage II
colon cancer, however, this is one of the larger
studies of its kind [6,14–16]. A direct consequence
of cohort size is a relatively low number of patients
within some subgroups of the survival analysis.
Since selection bias is highly unlikely due to the
prospective inclusion of this cohort, we have no
reason to question the accuracy of our data. An
increase in patient numbers, therefore, would only
lead to improved precision (i.e. smaller confidence
intervals) and would not change the trends in
Figure 2. (A) Overall survival stratified by N-stage. (B) Overall survival stratified by T-stage. (C) Overall survival stratified by lym-
phovascular invasion. (D) Overall survival stratified by differentiation grade. (E) Overall survival stratified by type of colectomy.
186 S. B€UTTNER ET AL.
survival depicted by our data. We therefore believe
that an increase of the number of patients in the
subgroups would still not lead us to conclude clin-
ically significant differences over these subgroups,
with regard to overall survival.
We conclude that pathology reports should bet-
ter describe the five high-risk factors in stage II
colon cancer, in order to enable proper patient
selection for further treatment. Of the five factors,
only the tumor differentiation grade was observed
to be prognostic in multivariable survival analysis.
Chemotherapy may be offered to patients only in
select instances, when a certain set of prognostic
markers is present. Further research into these
prognostic markers is warranted, as a definitive set
is still unavailable.
Disclosure statement
The authors report no conflicts of interest. The authors




Robert R. J. Coebergh van den Braak http://orcid.org/
0000-0001-9310-6629
Michael Doukas http://orcid.org/0000-0002-8611-840X
Jan N. M. IJzermans http://orcid.org/0000-0003-3558-
1039
References
[1] DeSantis CE, Lin CC, Mariotto AB, et al. Cancer treat-
ment and survivorship statistics, 2014. CA Cancer J
Clin. 2014;64:252–271.
[2] Figueredo A, Rumble RB, Maroun J, et al. Follow-up
of patients with curatively resected colorectal cancer:
a practice guideline. BMC Cancer. 2003;3:26.
[3] Al-Asfoor A, Fedorowicz Z, Lodge M. Resection ver-
sus no intervention or other surgical interventions
for colorectal cancer liver metastases. Cochrane
Database Syst Rev. 2008;CD006039.
[4] Gregoire E, Hoti E, Gorden DL, et al. Utility or futility
of prognostic scoring systems for colorectal liver
metastases in an era of advanced multimodal ther-
apy. Eur J Surg Oncol. 2010;36:568–574.
[5] Grossmann I, de Bock GH, van de Velde CJ, et al.
Results of a national survey among Dutch surgeons
treating patients with colorectal carcinoma. Current
opinion about follow-up, treatment of metastasis,
and reasons to revise follow-up practice. Colorect
Dis. 2007;9:787–792.
[6] D'Angelica M, Kornprat P, Gonen M, et al. Effect on
outcome of recurrence patterns after hepatectomy
for colorectal metastases. Ann Surg Oncol. 2011;
18:1096–1103.
[7] Poston GJ, Tait D, O'Connell S, et al. Diagnosis and
management of colorectal cancer: summary of NICE
guidance. BMJ. 2011;343:d6751.
[8] Edge SB, Compton CC. The American Joint
Committee on Cancer: the 7th edition of the AJCC
cancer staging manual and the future of TNM. Ann
Surg Oncol. 2010;17:1471–1474.
[9] Benson AB, III, Schrag D, Somerfield MR, et al.
American Society of Clinical Oncology recommenda-
tions on adjuvant chemotherapy for stage II colon
cancer. J Clin Oncol. 2004;22:3408–3419.
[10] Meyerhardt JA, Mangu PB, Flynn PJ, et al. Follow-up
care, surveillance protocol, and secondary preven-
tion measures for survivors of colorectal cancer:
American Society of Clinical Oncology clinical prac-
tice guideline endorsement. J Clin Oncol. 2013;
31:4465–4470.
[11] Dienstmann R, Salazar R, Tabernero J. Personalizing
colon cancer adjuvant therapy: selecting optimal
treatments for individual patients. J Clin Oncol.
2015;33:1787–1796.
[12] De Sousa EMF, Wang X, Jansen M, et al. Poor-prog-
nosis colon cancer is defined by a molecularly dis-
tinct subtype and develops from serrated precursor
lesions. Nat Med. 2013;19:614–618.
[13] Guideline “Colorectaal carcinoom 3.0”: The
Netherlands Comprehensive Cancer Organisation;
2014 [cited 2014 Apr 16]. Available from: http://
www.oncoline.nl/colorectaalcarcinoom.
[14] Quirke P, Morris E. Reporting colorectal cancer.
Histopathology. 2007;50:103–112.
[15] Branston LK, Greening S, Newcombe RG, et al. The
implementation of guidelines and computerised
forms improves the completeness of cancer path-
ology reporting. The CROPS project: a randomised
controlled trial in pathology. Eur J Cancer. 2002;
38:764–772.
[16] Cross SS, Feeley KM, Angel CA. The effect of four
interventions on the informational content of histo-
pathology reports of resected colorectal carcinomas.
J Clin Pathol. 1998;51:481–482.
[17] Woods YL, Mukhtar S, McClements P, et al. A survey
of reporting of colorectal cancer in Scotland: compli-
ance with guidelines and effect of proforma report-
ing. J Clin Pathol. 2014;67:499–505.
[18] Messenger DE, McLeod RS, Kirsch R. What impact
has the introduction of a synoptic report for rectal
cancer had on reporting outcomes for specialist
gastrointestinal and nongastrointestinal patholo-
gists? Arch Pathol Lab Med. 2011;135:1471–1475.
[19] Compton CC, Fielding LP, Burgart LJ, et al.
Prognostic factors in colorectal cancer. College of
American Pathologists Consensus Statement 1999.
Arch Pathol Lab Med. 2000;124:979–994.
[20] Maughan NJ, Morris E, Forman D, et al. The validity
of the Royal College of Pathologists' colorectal can-
cer minimum dataset within a population. Br J
Cancer. 2007;97:1393–1398.
[21] Andre T, Boni C, Navarro M, et al. Improved overall
survival with oxaliplatin, fluorouracil, and leucovorin
as adjuvant treatment in stage II or III colon cancer
in the MOSAIC trial. J Clin Oncol. 2009;27:3109–3116.
ACTA CHIRURGICA BELGICA 187
